NTSR1 and neoplasm: The prodrug system involved the reduction of nitroaromatic substrates to arylamines by NTR in hypoxic tumor environments, followed by bioorthogonal imination with aldehydes to produce the anticancer agent aza-RSV (Figure 2B).